Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients.

Pérez-Ramírez C, Cañadas-Garre M, Molina MÁ, Cabeza Barrera J, Faus-Dáder MJ.

Mutat Res. 2019 Jul - Sep;781:63-70. doi: 10.1016/j.mrrev.2019.04.001. Epub 2019 Apr 9. Review.

PMID:
31416579
2.

Cutaneous leishmaniasis associated with TNF-α blockers: a case report.

Nieto Gómez P, Casas Hidalgo I, Casas Hidalgo MP, Álvarez Sánchez R, Rodríguez Delgado A, Cabeza-Barrera J.

Eur J Hosp Pharm. 2019 Jul;26(4):233-234. doi: 10.1136/ejhpharm-2018-001521. Epub 2018 May 5.

PMID:
31338176
3.

Efficacy of enzalutamide and apalutamide in the treatment of non-metastasic castration-resistant prostate cancer: Indirect comparison.

Nieto-Gómez P, Ubago-Pérez R, Cabeza-Barrera J.

Actas Urol Esp. 2019 Sep;43(7):355-363. doi: 10.1016/j.acuro.2019.03.007. Epub 2019 May 24. English, Spanish.

PMID:
31133348
4.

Trends in endpoint selection and result interpretation in advanced non-small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study.

Fernández-López C, Calleja-Hernández MÁ, Balbino JE, Cabeza-Barrera J, Expósito-Hernández J.

Thorac Cancer. 2019 Apr;10(4):904-908. doi: 10.1111/1759-7714.13024. Epub 2019 Mar 13.

5.

Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes.

Caballero Romero Á, Delgado Ureña MT, Salmerón García A, Megías Fernández MT, Librada Porriño-Bustamante M, Cabeza Barrera J.

Anticancer Drugs. 2018 Oct;29(9):821-826. doi: 10.1097/CAD.0000000000000672. Review.

PMID:
30036190
6.

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.

Ríos-Tamayo R, Martín-García A, Alarcón-Payer C, Sánchez-Rodríguez D, de la Guardia AMDVD, García Collado CG, Jiménez Morales A, Jurado Chacón M, Cabeza Barrera J.

Drug Des Devel Ther. 2017 Aug 22;11:2399-2408. doi: 10.2147/DDDT.S115456. eCollection 2017. Review.

7.

Antidiabetic medications use trends in an Andalusian region from 2001 to 2014.

López-Sepúlveda R, García Lirola MÁ, Espínola García E, Jurado Martínez JM, Martín Sances S, Anaya Ordóñez S, Cabeza Barrera J.

Prim Care Diabetes. 2017 Jun;11(3):254-264. doi: 10.1016/j.pcd.2017.01.003. Epub 2017 Jan 23.

PMID:
28126469
8.

Effects of a primary care intervention to improve the quality of zolpidem prescriptions in elderly patients.

López-Sepúlveda R, García Lirola MÁ, Espínola García E, Martín Sances S, Anaya Ordóñez S, Jurado Martínez JM, Cabeza Barrera J.

Eur J Clin Pharmacol. 2017 Apr;73(4):455-461. doi: 10.1007/s00228-016-2180-4. Epub 2016 Dec 27.

PMID:
28028585
9.

Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent.

Sánchez-Ramos J, Dávila-Fajardo CL, Toledo Frías P, Díaz Villamarín X, Martínez-González LJ, Martínez Huertas S, Burillo Gómez F, Caballero Borrego J, Bautista Pavés A, Marín Guzmán MC, Ramirez Hernández JA, Correa Vilches C, Cabeza Barrera J.

Int J Cardiol. 2016 Dec 15;225:289-295. doi: 10.1016/j.ijcard.2016.09.088. Epub 2016 Sep 26.

PMID:
27744205
10.

Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.

Díaz-Villamarín X, Dávila-Fajardo CL, Martínez-González LJ, Carmona-Sáez P, Sánchez-Ramos J, Álvarez Cubero MJ, Salmerón-Febres LM, Cabeza Barrera J, Fernández-Quesada F.

Pharmacogenomics. 2016 Aug;17(12):1327-38. doi: 10.2217/pgs-2016-0056. Epub 2016 Jul 27.

PMID:
27464309
11.

Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancer.

Fernández-López C, Expósito-Hernández J, Arrebola-Moreno JP, Calleja-Hernández MÁ, Expósito-Ruíz M, Guerrero-Tejada R, Linares I, Cabeza-Barrera J.

Cancer Med. 2016 Sep;5(9):2190-7. doi: 10.1002/cam4.782. Epub 2016 Jul 23. Review.

12.

A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population.

Tong HY, Dávila-Fajardo CL, Borobia AM, Martínez-González LJ, Lubomirov R, Perea León LM, Blanco Bañares MJ, Díaz-Villamarín X, Fernández-Capitán C, Cabeza Barrera J, Carcas AJ; PGX-ACE Investigators Group.

PLoS One. 2016 Mar 15;11(3):e0150456. doi: 10.1371/journal.pone.0150456. eCollection 2016.

13.

Medication reconciliation at admission and discharge: an analysis of prevalence and associated risk factors.

Belda-Rustarazo S, Cantero-Hinojosa J, Salmeron-García A, González-García L, Cabeza-Barrera J, Galvez J.

Int J Clin Pract. 2015 Nov;69(11):1268-74. doi: 10.1111/ijcp.12701. Epub 2015 Jul 22.

PMID:
26202091
14.

Medication reconciliation at admission to surgical departments.

González-García L, Salmerón-García A, García-Lirola M, Moya-Roldán S, Belda-Rustarazo S, Cabeza-Barrera J.

J Eval Clin Pract. 2016 Feb;22(1):20-25. doi: 10.1111/jep.12403. Epub 2015 Jun 17.

PMID:
26083630
15.

Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis.

Gómez Peña C, Dávila-Fajardo CL, Martínez-González LJ, Carmona-Sáez P, Soto Pino MJ, Sánchez Ramos J, Moreno Escobar E, Blancas I, Fernández JJ, Fernández D, Correa C, Cabeza Barrera J.

Pharmacogenet Genomics. 2015 Aug;25(8):388-93. doi: 10.1097/FPC.0000000000000149.

PMID:
26049584
16.

FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis.

Dávila-Fajardo CL, van der Straaten T, Baak-Pablo R, Medarde Caballero C, Cabeza Barrera J, Huizinga TW, Guchelaar HJ, Swen JJ.

Pharmacogenomics. 2015;16(4):373-81. doi: 10.2217/pgs.14.178.

PMID:
25823785
17.

Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis.

Márquez A, Ferreiro-Iglesias A, Dávila-Fajardo CL, Montes A, Pascual-Salcedo D, Perez-Pampin E, Moreno-Ramos MJ, García-Portales R, Navarro F, Moreira V, Magro C, Caliz R, Ferrer MA, Alegre-Sancho JJ, Joven B, Carreira P, Balsa A, Vasilopoulos Y, Sarafidou T, Cabeza-Barrera J, Narvaez J, Raya E, Cañete JD, Fernández-Nebro A, Ordóñez Mdel C, de la Serna AR, Magallares B, Gomez-Reino JJ, González A, Martín J.

Arthritis Res Ther. 2014 Mar 11;16(2):R66. doi: 10.1186/ar4504.

18.

Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.

Dávila-Fajardo CL, Márquez A, Pascual-Salcedo D, Moreno Ramos MJ, García-Portales R, Magro C, Alegre-Sancho JJ, Balsa A, Cabeza-Barrera J, Raya E, Martín J.

Pharmacogenet Genomics. 2014 Jan;24(1):1-5. doi: 10.1097/FPC.0000000000000013.

PMID:
24253594
19.

Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate.

Dávila-Fajardo CL, Swen JJ, Cabeza Barrera J, Guchelaar HJ.

Pharmacogenomics. 2013 Jan;14(1):63-73. doi: 10.2217/pgs.12.183. Review.

PMID:
23252949
20.

[Salvage therapy with aliskiren in malignant familial hypertension in a breast-fed baby].

Belda-Rustarazo S, Vallejo-Rodríguez I, Molina-Carballo A, Cabeza Barrera J.

Farm Hosp. 2011 Nov-Dec;35(6):343-4. doi: 10.1016/j.farma.2010.11.002. Epub 2011 May 11. Spanish. No abstract available.

PMID:
21565539
21.

Topical endotracheal mitomycin C as a complementary treatment for endoscopic treatment of recurrent laryngotracheal stenosis.

Cortés de Miguel S, Cabeza Barrera J, Gallardo Medina M, Cassini Gómez de Cádiz LF, Salmerón-García A, Rodríguez Lucas F.

Farm Hosp. 2011 Jan-Feb;35(1):32-5. doi: 10.1016/j.farma.2010.04.002. Epub 2010 Dec 16. Review. English, Spanish.

PMID:
20663704
22.

[Methoxy polyethylene glycol-epoetin beta (Mircera) in the treatment of a patient with chronic kidney disease presenting late-onset hypersensitivity to other epoetins].

Dávila Fajardo CL, Peña Ortega M, Cabeza Barrera J, Prados Garrido MD.

Nefrologia. 2010;30(3):372-3. doi: 10.3265/Nefrologia.pre2010.Mar.10310. Spanish. No abstract available.

23.

Detection of adverse drug reactions through the minimum basic data set.

Salmerón-García A, Cabeza Barrera J, Vergara Pavón MJ, Román Márquez E, Cortés de Miguel S, Vallejo-Rodríguez I, Raya García S, Casado Fernández E.

Pharm World Sci. 2010 Jun;32(3):322-8. doi: 10.1007/s11096-010-9372-2. Epub 2010 Mar 6.

PMID:
20213432
24.

[Ophthalmic tacrolimus cream for the treatment of immunological corneal ulcers].

Dávila-Fajardo CL, Cabeza Barrera J, Vallejo Rodríguez I, García Serrano JL.

Farm Hosp. 2009 Mar-Apr;33(2):112-3. Spanish. No abstract available.

PMID:
19480801
25.

[Getting ready for a potential avian influenza pandemics. The contribution of hospital pharmacy].

Cabeza Barrera J, Bautista Paloma FJ.

Farm Hosp. 2006 Jul-Aug;30(4):201-5. Spanish. No abstract available.

26.

[Inappropriate commercial presentation of selected drugs and associated overcost].

Toledano Mayoral G, Salmerón García A, Román Márquez E, Cabeza Barrera J.

Farm Hosp. 2006 May-Jun;30(3):195-6. Spanish. No abstract available.

27.

[Quality of clinical trials provided in GINF].

Salmerón-García A, Toledano Mayoral G, Román Márquez E, Cabeza Barrera J, Damas Fernández-Fígares M.

Farm Hosp. 2005 Sep-Oct;29(5):346-7. Spanish. No abstract available.

28.

[Adequacy of pharmaceutic dosage forms of antiretroviral therapy].

Cabeza Barrera J, García Lirola MA, Zamora Ardoy MA, Díez García LF.

Med Clin (Barc). 2000 Mar 11;114(9):356-8. Spanish. No abstract available.

PMID:
10786340
29.

[Adoption of new medications by prescribing physicians. The innovator physician].

García Lirola MA, Cabeza Barrera J, Rodríguez Espejo M, Alegre del Rey E, Rabadán Asensio A.

Aten Primaria. 2000 Jan;25(1):22-8. Spanish.

30.

[The quality of antibacterial prescription in a primary care district. Its evolution in 1994-1995].

García Lirola MA, Cabeza Barrera J, Ignacio García JM, Rabadán Asensio A.

Aten Primaria. 1997 May 31;19(9):487-92. Spanish.

PMID:
9264685

Supplemental Content

Loading ...
Support Center